Clinical trial
Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic…
NCT00324077 · Bristol-Myers Squibb, Industry · Withdrawn
Key facts
| NCT number | NCT00324077 |
|---|---|
| Title | Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase |
| Official title | A Phase I Dose Escalation Study of the Combination of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Myeloid Leukemia, Chronic, Chronic-Phase |
| Intervention type | Drug |
| Interventions | Dasatinib in combination with imatinib |
| Enrollment | 0 |
| Start date | Aug 1, 2006 |
| Primary completion | Feb 1, 2007 |
| First posted | May 10, 2006 |
| Last update posted | Feb 17, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: